Results 251 to 260 of about 178,517 (322)

Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. [PDF]

Blood Cancer J
Kismali G, Manyam G, Jain N, Ivan C, Lamothe B, Ayres ML, Iles LR, Wierda WG, Gandhi V.   +8 more
europepmc   +1 more source

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

, 2019
Motoo Nagane, Yoshitaka Narita, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa   +12 more
openalex   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

Int J Mol Sci
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, Billia F, Lai PFH, Abdel-Qadir H, Nanthakumar K.   +9 more
europepmc   +1 more source

Bruton's tyrosine kinase (Btk) と結合する新規分子の同定とその解析 [PDF]

マツシタ, マサト, 松下, 正人
core  

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors. [PDF]

JCI Insight
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE.   +31 more
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. [PDF]

Mol Cancer Ther
Li W, Sano R, Apatira M, DeAnda F, Gururaja T, Yang M, Lundgaard G, Pan C, Liu J, Zhai Y, Yoon WH, Wang L, Tse C, Souers AJ, Lee CH.   +14 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax. [PDF]

Blood Cancer J
Coughlin CA, Chahar D, Lekakis M, Youssfi AA, Li L, Roberts E, Gallego NC, Volmar CH, Landgren O, Brothers S, Griswold AJ, Amador C, Bilbao D, Maura F, Schatz JH.   +14 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]

Oncotarget
Patel JN, Singh J, Ghosh N.
europepmc   +1 more source

Bruton's tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia. [PDF]

J Neuroinflammation
Xu LL, Yang S, Zhou LQ, Chu YH, Pang XW, You YF, Zhang H, Zhang LY, Zhu LF, Chen L, Shang K, Xiao J, Wang W, Tian DS, Qin C.   +14 more
europepmc   +1 more source